Shaanxi Meibang Pharmaceutical Group Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Shaanxi Meibang Pharmaceutical Group Co., Ltd. carries a market capitalization of 2.45B, placing it among publicly traded companies globally. Its enterprise value stands at 2.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.45B |
| Enterprise Value | 2.70B |
Share Statistics
Shaanxi Meibang Pharmaceutical Group Co., Ltd. currently has 135.20M shares outstanding.
| Shares Outstanding | 135.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shaanxi Meibang Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 57.60. The price-to-sales ratio is 3.74, and the price-to-book ratio stands at 4.51.
| PE Ratio | 57.60 |
| PS Ratio | 3.74 |
| PB Ratio | 4.51 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | 26.24 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shaanxi Meibang Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 29.33 and an EV/FCF ratio of 22.58. The EV/Sales ratio of 3.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 29.33 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.23 |
| EV / EBITDA | 29.33 |
| EV / EBIT | 29.33 |
| EV / FCF | 22.58 |
Financial Position
Shaanxi Meibang Pharmaceutical Group Co., Ltd. maintains a current ratio of 2.39, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.29, indicating elevated leverage, while an interest coverage ratio of 149.83 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.39 |
| Quick Ratio | 1.29 |
| Debt / Equity | 13.29 |
| Debt / EBITDA | 1.72 |
| Interest Coverage | 149.83 |
Financial Efficiency
Shaanxi Meibang Pharmaceutical Group Co., Ltd. posts a return on equity of 7.98 and a return on invested capital of 5.77.
| Return on Equity (ROE) | 7.98 |
| Return on Assets (ROA) | 2.85 |
| Return on Invested Capital (ROIC) | 5.77 |
| Return on Capital Employed (ROCE) | 6.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.76 |
Taxes
Over the trailing twelve months, Shaanxi Meibang Pharmaceutical Group Co., Ltd. has paid 12.72M in income taxes, reflecting an effective tax rate of 18.99.
| Income Tax | 12.72M |
| Effective Tax Rate | 18.99 |
Stock Price Statistics
Shaanxi Meibang Pharmaceutical Group Co., Ltd.'s stock has declined approximately -6.98511% over the past 52 weeks. The 50-day moving average sits at 20.54, while the 200-day moving average is 21.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.98511% |
| 50-Day Moving Average | 20.54 |
| 200-Day Moving Average | 21.80 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shaanxi Meibang Pharmaceutical Group Co., Ltd. generated 835.32M in revenue and converted that into 54.27M in net income, yielding earnings per share of 0.40. EBITDA reached 92.11M, while operating income came in at 92.11M.
| Revenue | 835.32M |
| Gross Profit | 295.51M |
| Operating Income | 92.11M |
| Pretax Income | 66.99M |
| Net Income | 54.27M |
| EBITDA | 92.11M |
| EBIT | 92.11M |
| Earnings Per Share (EPS) | 0.40 |
Balance Sheet
Shaanxi Meibang Pharmaceutical Group Co., Ltd. holds 583.00M in cash and equivalents against 158.00M in total debt, resulting in a net debt position of -138.86M. Total book value stands at 693.23M, with working capital of 626.25M providing operational flexibility.
| Cash & Cash Equivalents | 583.00M |
| Total Debt | 158.00M |
| Net Debt | -138.86M |
| Equity (Book Value) | 693.23M |
| Book Value Per Share | 5.06 |
| Working Capital | 626.25M |
Cash Flow
After subtracting -119.12M in capital expenditures, free cash flow totaled -119.12M - equivalent to -0.87 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -119.12M |
| Free Cash Flow | -119.12M |
| FCF Per Share | -0.87 |
Margins
Shaanxi Meibang Pharmaceutical Group Co., Ltd. operates with a gross margin of 35.38, reflecting its pricing power and cost economics. The operating margin of 11.03 and net profit margin of 6.50 provide insight into operational efficiency.
| Gross Margin | 35.38 |
| Operating Margin | 11.03 |
| Pretax Margin | 8.02 |
| Profit Margin | 6.50 |
| EBITDA Margin | 11.03 |
Dividends & Yields
The company's payout ratio of 20.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.08 |
| Dividend Yield | N/A |
| Payout Ratio | 20.17 |
| Shareholder Yield | -1.97 |
| FCF Yield | 3.81 |
Scores
Shaanxi Meibang Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 3.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.84 |